Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TT-00434 in Advanced Solid Tumors
NCT04830501Phase 1Completed
- Sponsor
- TransThera Biosciences
- Start
- Jul 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TT-00434 in solid tumor (advanced stage), sponsored by TransThera Biosciences. Primary endpoints: Dose Limiting Toxicity and Incidence of Adverse Events. Started Jul 2021; status: completed.
02
Drugs
TT-00434
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04830501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04830501.